How promising science reaches people: scale, economics, adoption, and access.
A study visit at the kitchen table could remove a long journey. Good trial design also asks who gains access, who takes on new work, and how the evidence stays dependable.
4 min read
A patient-pathway funnel, starter-dose capacity check and financial threshold show why convenient dosing still needs an operating system.
Recent generic-pressure reporting anchors a fictional sales-force redeployment and productivity model.
![Reported cardiovascular event proportions. Wegovy: 6.5; Placebo: 8. Participants with event (%). FDA 2024 announcement [1]; absolute difference 1.5 percentage points.](/images/consulting/wegovy-outcomes-evidence-access-dossier-record.svg)
Wegovy’s outcomes result and Medicare’s next negotiation cycle frame evidence, budget and eligible-population planning.
Repatha’s historical reset and recent growth provide context for a fictional launch team’s break-even calculation.
![Historical Humira U.S. sales index. 2022 index: 100; 2023 index: 65. Sales index (2022 = 100). Derived from disclosed 35% U.S. annual decline [1]; not units.](/images/consulting/humira-loss-exclusivity-price-volume-bridge-record.svg)
Historical U.S. erosion and 2026 global reporting inform a hypothetical biosimilar-response model.
Sovaldi and current Medicare pricing implementation frame an indication-specific budget-impact assignment.
A durable therapy changes more than a treatment schedule. It asks healthcare to think differently about follow-up, evidence, payment, and the years that come after.
4 min read
Define the baseline, deliverables and economic perspective before attributing time or money saved to an intervention.
Historical financing events and a runway model clarify what a capital headline can—and cannot—tell a reader.
A MASH case shows why a biomarker result, an approval and a commercial forecast answer different questions.
Clinical endpoints, monitoring requirements and patient persistence belong in the same commercial plan.
A corrected public cost study shows why a headline R&D estimate is a starting point for analysis, not a universal budget or price justification.
Recent FDA prevention counts provide a signal about supply interventions, while leaving product-level access questions unresolved.
A new antibiotic can be most valuable when it is used carefully. That creates a revealing challenge for how we fund discovery, protect effectiveness, and keep treatment available.
4 min read
A record approval year offers an opportunity to examine the operational steps between regulatory entry and patient access.
The 2023 decision puts a measurable boundary around a broad molecular-platform narrative.
Dendreon’s 2010–2014 record separates clinical value, operating revenue, and financing resilience.
The CMS access model makes outcome contracting, treatment logistics, and follow-up separate milestones.